Ovid Therapeutics Inc. (OVID): Price and Financial Metrics
OVID Price/Volume Stats
| Current price | $3.23 | 52-week high | $4.14 |
| Prev. close | $3.21 | 52-week low | $2.57 |
| Day low | $3.17 | Volume | 176,600 |
| Day high | $3.29 | Avg. volume | 197,242 |
| 50-day MA | $3.26 | Dividend yield | N/A |
| 200-day MA | $3.43 | Market Cap | 228.39M |
OVID Stock Price Chart Interactive Chart >
Ovid Therapeutics Inc. (OVID) Company Bio
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was founded in 2014 and is based in New York City, New York.
Latest OVID News From Around the Web
Below are the latest news stories about OVID THERAPEUTICS INC that investors may wish to consider to help them evaluate OVID as an investment opportunity.
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide further evidence characterizing OV350 and its anticipated seizure reduction and neuroprotective profile, including its ability to reverse diazepam-resistant seizures NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines des |
Ovid Therapeutics (OVID) Upgraded to Buy: Here's WhyOvid Therapeutics (OVID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Q3 2023 Ligand Pharmaceuticals Inc Earnings CallQ3 2023 Ligand Pharmaceuticals Inc Earnings Call |
Ovid Therapeutics Inc (OVID) Reports Q3 2023 Financial ResultsCompany extends cash runway into 2026 and anticipates five clinical and regulatory milestones in the next 15 months |
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate UpdatesReceived a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash runway into 2026 Clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome remain on track; Takeda anticipates regulatory filings in its fiscal year 2024 Ovid recently hosted an R&D Day during which the Company announced indication and formulation expansions |
OVID Price Returns
| 1-mo | 5.90% |
| 3-mo | 2.87% |
| 6-mo | -9.27% |
| 1-year | 0.31% |
| 3-year | -10.03% |
| 5-year | 258.89% |
| YTD | 0.31% |
| 2023 | 73.12% |
| 2022 | -42.06% |
| 2021 | 38.96% |
| 2020 | 11.33% |
| 2019 | 71.49% |
Loading social stream, please wait...